Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen To Pursue Functional Genomics

Premium

CARLSBAD, Calif.--Invitrogen named two new board members to guide the development of a new division focused on applying Invitrogen's gene cloning and expression technologies to enable functional genomics studies for drug discovery, diagnostic development, and crop improvement. James Glynn was appointed senior vice-president and member of the board of directors, and Lewis Shuster, chief financial officer of Pharmacopeia, was also named to the board.

Invitrogen CEO Lyle Turner said the company is gearing up to expand upon its base of proprietary gene cloning and expression technologies and apply the technology platforms for advanced functional genomics research.

Filed under

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.